Merrimack Pharmaceuticals Inc

Merrimack Pharmaceuticals — Merger or Acquisition (January 2017)

26 slides from Merrimack Pharmaceuticals's merger presentation, Jan 9, 2017

  1. Slide 1: Merrimack Pharmaceuticals: A Refocused R&D Company

    Merrimack Pharmaceuticals: A Refocused R&D Company January 2017 Exhibit 99.2

  2. Slide 2: Forward-looking statements

    This presentation contains forward-looking statements of the Company that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements. Forward looking statements can be identified by the use of

  3. Slide 3: Merrimack: Refocused R&D Biopharmaceutical Company

    Merrimack: Refocused R&D Biopharmaceutical Company Definitive agreement with Ipsen to sell ONIVYDE® & generic version of doxorubicin hydrochloride (HCI) liposome injection (“generic DOXIL®”) Merrimack will receive consideration of up to $1.025B, including $450M in potential future cash milestone pay

  4. Slide 4: Benefits of the Transaction for Key Stakeholders

    Benefits of the Transaction for Key Stakeholders Stockholders Stockholders receive immediate and compelling value for ONIVYDE® Merrimack expects to pay a one-time special cash dividend of at least $200M, which equates to approximately $1.54 per common share (1) Right to participate in the upside pot

  5. Slide 5: Overview of the Sale of ONIVYDE & Generic DOXIL

    Overview of the Sale of ONIVYDE® & Generic DOXIL® Total Potential Consideration $1.025B in cash, plus up to $33 million in net milestone payments retained by Merrimack pursuant to Merrimack’s exclusive licensing agreement with Shire Upfront Payment at Closing $575M in cash Potential ONIVYDE® Approva

  6. Slide 6: Strengthening Our Financial Position

    Strengthening Our Financial Position Capital structure appropriate for an R&D-focused biopharmaceutical company Invest $125 million to develop the Company’s streamlined oncology pipeline, such that Merrimack will be funded into the second half of 2019 Plan to extinguish $175M in outstanding Senior S

  7. Slide 7: Delivering Shareholder Value for Merrimack

    Delivering Shareholder Value for Merrimack ~$1.54 cash + ONIVYDE milestones + Pipeline success è Significant upside 100% pass-through of milestone payments may mean ~$5 / share(1) in dividends if ONIVYDE label expansion efforts are successful Pipeline success has potential to dramatically further dr

  8. Slide 8: New Merrimack: Driving Value Across Focused Streamlined Oncology Pipeline

    New Merrimack: Driving Value Across Focused Streamlined Oncology Pipeline

  9. Slide 9: New Merrimack: Driving Value Across Focused Streamlined Oncology Pipeline

    New Merrimack: Driving Value Across Focused Streamlined Oncology Pipeline Strategic Shift: Going forward Merrimack is dedicated to accelerating the time to clinically meaningful data in precisely defined patient populations, while optimizing the use of available resources The Merrimack Board determi

  10. Slide 10: Seribantumab (MM-121)

    Seribantumab (MM-121) Seribantumab is a first-in class monoclonal antibody targeting HER3 Seribantumab has the potential to transform patient care in heregulin positive patients backed by the extensive clinical data package and by the strong biomarker hypothesis

  11. Slide 11: Seribantumab Designed to Target Biomarker Positive Patients: SHERLOC NSCLC Study

    Seribantumab Designed to Target Biomarker Positive (BM+) Patients SHERLOC NSCLC Study Goal: Accelerated data read-out to validate biomarker and drug hypothesis based on retrospective analysis of clinical data The Change: Amend the ongoing SHERLOC study from 280 patients looking at OS as the primary

  12. Slide 12: Seribantumab: ER/PR+ Breast Cancer Study

    Seribantumab Designed to Target Biomarker Positive (BM+) Patients 2. ER/PR+ Breast Cancer Study Goal: Unlock the full potential of seribantumab Establish the cross-indication impact by demonstrating the value of treating HRG positive cancer patients with seribantumab Breast Cancer: Breast cancer is

  13. Slide 13: Stratification by HRG status on Comparator and Active Arm

    Stratification by HRG status on Comparator and Active Arm Seribantumab reverses the negative prognostic effect of high HRG in patients The mPFS for patients receiving exemestane alone was 3.5 months for HRG negative patients and 1.9 months for HRG positive patients (HR = 3.4, 95% CI[1.48-7.85], p=0.

  14. Slide 14: Rationale for a Breast Cancer Study

    Rationale for a Breast Cancer Study: Potential for dramatic clinical benefit in aromatase inhibitor (AI) naïve, HRG+ patients Separating HRG+ patients based on prior exposure to aromatase inhibitors (AI) reveals that patients who are AI sensitive (naïve) have the potential for dramatic clinical bene

  15. Slide 15: Istiratumab (MM-141)

    Istiratumab (MM-141) Istiratumab is a bispecific tetravalent antibody and a potent inhibitor of the PI3K/AKT/mTOR pathway by targeting IGF1-R and HER3

  16. Slide 16: MM-141 Activity and CARRIE Study Modification

    MM-141 Activity in a PanC Xenograft Model Mean Cycles on Therapy Phase 1 Data Presented at AACR 2015 Istiratumab (MM-141): Accelerate top-line data: Modify CARRIE Data Presented at ASCO GI 2015 CARRIE front-line pancreatic cancer study: Goal: Accelerated data read-out to validate biomarker and drug

  17. Slide 17: MM-310

    MM-310 A novel antibody directed nanotherapeutic (ADN) that contains a prodrug of docetaxel and targets the EphA2 receptor MM-310 utilizes the same proprietary nano-liposomal technology as ONIVYDE® Launching a Phase 1 study with MM-310 enrolling prostate, ovarian, bladder, gastric and lung cancer pa

  18. Slide 18: MM-310 Designed to Improve the Therapeutic Window

    MM-310 was designed specifically to improve the therapeutic window via three mechanisms: The encapsulation of docetaxel maximizes the exposure in the tumor through selective accumulation in solid tumors and a slow and sustained release mechanism The stable encapsulation of a docetaxel prodrug furthe

  19. Slide 19: Summary

    Summary (© 2017 Merrimack Pharmaceuticals, Ine, All rights reserved,

  20. Slide 20: Merrimack is Funded Through Significant Value Inflection Events

    Merrimack is Funded Through Significant Value Inflection Events 2017 2018 January 2017: File proxy materials related to Special Meeting of Stockholders February 2017: Special Meeting of Stockholders to approve transaction Q1 2017: Receive all required approvals and complete transaction 2017: Initiat

  21. Slide 21: The New Merrimack Opportunity

    The New Merrimack Opportunity Focused on three leading product candidates Committed to delivering innovative oncology treatments for cancer patients, while creating value for stockholders Capital structure to support and sustain strategic shift to earlier-stage, R&D-focused biopharmaceutical company

  22. Slide 22: Appendix: Supporting Information on Development Stage Assets

    Appendix: Supporting Information on Development Stage Assets

  23. Slide 23: Seribantumab: Phase 2 NSCLC Study Design

    Seribantumab: Converted Phase 2 NSCLC Study Design Patient population Heregulin-positive, non-small cell lung cancer Locally advanced or metastatic disease Prior exposure to no more than three lines of prior therapy Primary endpoint: PFS Randomization 2:1 (140 patients expected) Experimental Arm 3 g

  24. Slide 24: Seribantumab: Phase 2 ER/PR+ Breast Cancer Study Design

    Seribantumab: Phase 2 ER/PR+ Breast Cancer Study Design Patient population Heregulin-positive, HER2-, ER/PR+ breast cancer Locally advanced or metastatic disease Prior exposure to CDKi No more than three lines of prior therapy Primary endpoint: PFS Randomization 2:1 Experimental Arm Seribantumab + F

  25. Slide 25: MM-310 Planned Phase 1 Clinical Trial Design

    MM-310 Planned Phase 1 Clinical Trial Design Phase 1 Dose escalation Build combination regimens Single Agent Expansion Cohort EphA2 positive

  26. Slide 26: Rationale behind MM-310: Steep Dose-Response Relationship of Docetaxel

    Rationale behind MM-310: Steep Dose-Response Relationship of Docetaxel Docetaxel dose correlates with clinical benefit Docetaxel dose correlates hematologic events

Merrimack Pharmaceuticals — Merger or Acquisition (January 2017) on 6ix